Key result
Cyclosporine A was associated with significantly higher aortic pulse wave velocity compared to tacrolimus in renal transplant recipients (9.33 vs. 8.54; p < 0.01).
Why the study?
Does Cyclosporine A compared to Tacrolimus increase pulse wave velocity and arterial stiffness in renal transplant recipients?
Observational (n=152)
Does Cyclosporine A compared to Tacrolimus increase pulse wave velocity and arterial stiffness in renal transplant recipients?
Cyclosporine A is associated with higher arterial stiffness and a more unfavorable cardiovascular risk profile compared to tacrolimus in renal transplant recipients.
Answers are grounded in this paper and cite their sources.
May favor tacrolimus to limit arterial stiffness post-transplant; hypothesis-generating for cardiovascular outcomes.
BACKGROUND: Pulse wave velocity (PWV) is a marker of the arterial wall stiffness and independent cardiovascular risk factor in hemodialysis patients. Cyclosporine A (CyA) and tacrolimus (TAC) are known to differ in the influence on cardiovascular risk factors in renal transplant recipients. Recent studies suggest that CyA may decrease arterial compliance. The aim of the study was to assess the influence of CyA and TAC on the PWV and arterial wall stiffness in renal transplant recipients. METHODS: The study population consisted of two groups of cadaveric renal transplant recipients, 76 patients each, matched for age, sex, blood pressure, body mass index, and length of the post-transplant follow-up. PWV between carotid and femoral artery was measured using a Complior device. Fasting blood was sampled for serum creatinine, lipid profile, uric acid, glucose, and C-reactive protein. RESULTS: Aortic pulse wave velocity -- a marker of increased arterial stiffness -- was significantly higher in CyA group compared with TAC group (9.33 +/- 2.10 vs. 8.54 +/- 1.35, respectively; p < 0.01). Uric acid, total cholesterol, triglycerides, and LDL-cholesterol concentrations were significantly higher in CyA group. Significant correlations were found between PWV and age, systolic and diastolic blood pressure, and fasting glucose in the CyA group, but only between PWV and age in TAC group. CONCLUSION: CyA-based immunosuppressive therapy is associated with an unfavorable profile of cardiovascular risk factors and increased arterial stiffness in renal transplant recipients.
No takes yet. Share an insight, caveat, or question.
Stróżecki et al. (2007) conducted an observational in Renal transplant recipients (n=152). Cyclosporine A (CyA) vs. Tacrolimus (TAC) was evaluated on Aortic pulse wave velocity (p=< 0.01). Cyclosporine A was associated with significantly higher aortic pulse wave velocity compared to tacrolimus in renal transplant recipients (9.33 vs. 8.54; p < 0.01).
Synapse has enriched 10 related papers. Consider them for comparative context: